R. Tschumper

发表

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.

T. Shanafelt, N. Kay, D. Jelinek, 2008, Leukemia research.

Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells

X. Wu, D. Jelinek, R. Tschumper, 2013, Leukemia.

Induction of the rat prodynorphin gene through Gs-coupled receptors may involve phosphorylation-dependent derepression and activation

C. McMurray, C. Spiro, L. Lin, 1994, Molecular and cellular biology.

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

T. Shanafelt, G. Dewald, S. Geyer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A rare case of selective Igκ chain deficiency: Biologic and clinical implications.

J. Katzmann, J. Mills, D. Jelinek, 2020, The Journal of allergy and clinical immunology.

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.

Thomas S. Lin, M. Grever, J. Byrd, 2009, Blood.

Selective Induction of DNA Repair Pathways in Human B Cells Activated by CD4+ T Cells

D. Jelinek, G. Nowakowski, R. Tschumper, 2010, PloS one.

Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.

N. Kay, D. Jelinek, Wenting Wu, 2010, Blood.

Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis

Deborah A. Bowen, T. Shanafelt, S. Slager, 2009, Leukemia & lymphoma.

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

Deborah A. Bowen, T. Shanafelt, S. Slager, 2008, British journal of haematology.

Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry.

A. Dispenzieri, J. Katzmann, M. Ramirez-Alvarado, 2014, Journal of proteome research.

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

J. Byrd, T. Kipps, R. Fonseca, 2010, Cancer genetics and cytogenetics.

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.

M. Grever, J. Byrd, T. Shanafelt, 2006, Leukemia research.

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

T. Shanafelt, G. Dewald, S. Geyer, 2008, British journal of haematology.

Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study

Deborah A. Bowen, T. Habermann, T. Shanafelt, 2017, American journal of hematology.

Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS.

A. Dispenzieri, J. Katzmann, D. Jelinek, 2014, Journal of proteome research.

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Lisa L. Smith, M. Grever, J. Byrd, 2006, Blood.

Early treatment of high‐risk chronic lymphocytic leukemia with alemtuzumab and rituximab

Deborah A. Bowen, T. Shanafelt, N. Kay, 2008, Cancer.

The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).

Deborah A. Bowen, T. Shanafelt, S. Slager, 2007 .

Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis

T. Shanafelt, S. Slager, Ruchi G. Sharma, 2013, British journal of haematology.

Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies

D. Jelinek, R. Tschumper, S. A. Mihalcik, 2010, Cell cycle.

Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia.

T. Shanafelt, G. Dewald, N. Kay, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extracellular vesicle proteomic analysis leads to the discovery of HDGF as a new factor in multiple myeloma biology

D. Jelinek, Trupti Vardam-Kaur, Sophia J Quinton, 2022, Blood advances.

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.

T. Shanafelt, G. Dewald, J. Hoyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies.

Roman M. Ženka, V. Sarangi, D. Jelinek, 2015, Journal of proteome research.

Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.

T. Shanafelt, G. Dewald, S. Geyer, 2008, The Journal of clinical investigation.

ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype

N. Kay, D. Jelinek, J. Nolz, 2005, Leukemia.

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia

J. O'fallon, G. Dewald, N. Kay, 2003, British journal of haematology.

Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia

A. Tefferi, G. Dewald, S. Geyer, 2001, British journal of haematology.

B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells

S. Slager, E. Braggio, N. Kay, 2021, Blood Cancer Journal.

Identification of a global gene expression signature of B-chronic lymphocytic leukemia.

Yuhai Tu, Stephen J Iturria, Jorge Lepre, 2003, Molecular cancer research : MCR.

Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.

D. Jelinek, B. Arendt, D. Walters, 2018, Experimental hematology.

Stage-Specific Non-Coding RNA Expression Patterns during In Vitro Human B Cell Differentiation into Antibody Secreting Plasma Cells

D. Jelinek, D. Hoelzinger, D. Walters, 2022, Non-coding RNA.

LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

Albert Gutierrez, Renee C Tschumper, T. Shanafelt, 2010, Blood.

Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse

R. Fonseca, T. Shanafelt, M. Barrett, 2012, Leukemia.

cyclophosphamide, and rituximab lymphocytic leukemia patients treated with pentostatin, Mcl-1 expression predicts progression-free survival in chronic

M. Grever, J. Byrd, N. Heerema, 2013 .

Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-D-J Intraclonal Variation Using Massively Parallel Pyrosequencing

Y. Asmann, Asif Hossain, A. Dispenzieri, 2012, Oncotarget.

Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines

W. Sandborn, D. Jelinek, D. McKean, 2005, Journal of Pharmacology and Experimental Therapeutics.

Differentiation of Chronic Lymphocytic Leukemia B Cells into Immunoglobulin Secreting Cells Decreases LEF-1 Expression

N. Kay, D. Jelinek, C. Zent, 2011, PloS one.

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

E. Campo, A. Navarro, K. Stamatopoulos, 2020, Blood.

Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS.

N. Kay, D. Jelinek, D. Muddiman, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia

T. Shanafelt, N. Kay, D. Jelinek, 2019, Oncotarget.

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.

Irene Ghobrial, Robert A Kyle, Rafael Fonseca, 2006, Blood.

Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

J. Keats, G. Ahmann, R. Fonseca, 2008, Blood.

Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.

R. Fonseca, T. Shanafelt, S. Slager, 2015, Blood.

Deep sequencing identi fi es genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia

R. Fonseca, T. Shanafelt, S. Slager, 2014 .

Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome

T. Habermann, T. Shanafelt, S. Slager, 2013 .

Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.

H. R. Bergen, A. Dispenzieri, M. Ramirez-Alvarado, 2016, Clinical chemistry.

Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation

D. Jelinek, B. Arendt, D. Walters, 2014, Oncotarget.

Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation

A. Dispenzieri, X. Wu, K. Henderson, 2012, Leukemia.

Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.

L. Rassenti, T. Kipps, T. Shanafelt, 2005 .

Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.

M. Grever, J. Byrd, G. Dewald, 2004 .

ABCG2 Is Expressed in a Small Population of Circulating CLL B-Cells Characterized by Expression of Self-Renewal and Early B-Cell Development Genes and Resistance to Therapy

N. Kay, D. Jelinek, G. Nowakowski, 2008 .

Presence of Immunoglobulin Heavy Chain Gene (IGH) Translocations in Chronic Lymphocytic Leukemia Is Related to Poor Prognosis.

T. Shanafelt, N. Kay, D. Jelinek, 2007 .

Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.

T. Shanafelt, M. Tallman, R. Stone, 2021, Blood.

Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX

A. Dispenzieri, X. Wu, K. Henderson, 2011, Leukemia.

Somatic Hyperrepair: A Novel Tumor Suppression Mechanism for Germinal Center B Cells.

D. Capello, D. Jelinek, G. Nowakowski, 2009 .

Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

T. Arora, J. Westendorf, D. Jelinek, 1997, The Journal of clinical investigation.

Dissection of the signalling requirements of interleukin-6-stimulated myeloma cell growth.

D. Jelinek, R. Tschumper, J. French, 2000, Acta oncologica.

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.

T. Shanafelt, G. Dewald, J. Hoyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.

M. Grever, J. Byrd, T. Shanafelt, 2009, Blood.